Inflammation/Immunology

Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator.

DS79182026 is an inhibitor of hepcidin production. DS79182026 exhibits hepcidin lowering ability in IL-6-induced acute inflammatory mouse model.

Taraxerol (Standard) is the analytical standard of Taraxerol. This product is intended for research and analytical applications. Taraxerol is isolated from Taraxacum mongolicum, and has anti-inflammtory and anti-cancer effects. Taraxerol attenuates acute inlammation through inhibition of NF-κB signaling pathway. Taraxerol induces cell apoptosis.

hIgG-hFc receptor-IN-2 is a hFcRn inhibitor with an IC₅₀ of 6 μM for human hFcRn. hIgG-hFc receptor-IN-2 blocks the protein-protein interaction between human IgG and the soluble extracellular domain of hFcRn. hIgG-hFc receptor-IN-2 serves as a tool for studying FcRn biology and a starting point for developing orally available small molecule hFcRn inhibitors. hIgG-hFc receptor-IN-2 can be used for the research of autoimmune disease.

SB-201993 is a selective leukotriene B₄ (LTB4) receptor antagonist with a K_i=7.6 nM for LTB4 receptors on human inflammatory cells. SB-201993 inhibits calcium mobilization in inflammatory cells and 5-lipoxygenase activity, exerting anti-inflammatory effects. SB-201993 is promising for research of inflammatory diseases (e.g., dermatitis, arthritis).

Anti-inflammatory agent 77 (C12) is a β-cycloacinamide derived mono-carbonyl curcumin analog and an inhibitor of interleukin-6 (IL-6). Anti-inflammatory agent 77 can be used in the study of wound healing.

[Des-Arg10]-HOE I40 is a potent bradykinin B1 receptor antagonist.

KF15766 (compd 34E) is an orally active TXA₂ and H₁ dual antagonist with K_is of 740 and 20 nM. KF15766 can be used for antiallergic research.

CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site.

Anti-CD11a Antibody (AL-57) is a monoclonal antibody targeting human CD11a. Anti-CD11a Antibody (AL-57) binds to HA cells in a dose-dependent manner but did not bind to LA cells. Anti-CD11a Antibody (AL-57) preferentially binds to the active conformation of LFA-1 and blocks LFA-1-mediated adhesion and lymphocyte proliferation. Anti-CD11a Antibody (AL-57) can be used for the research of inflammatory and autoimmune diseases.

DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.

Anti-PRNP Antibody is a monoclonal antibody that targets PRNP. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-PRNP Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Korepimedoside C (Epimedin I), a flavonol glycoside, is isolated from the aerial parts of Epimedium koreanum Nakai. Epimedium koreanum Nakai is a famous Chinese herbal medicine for the research of impotence, osteoporosis, immune suppression and cardiovascular diseases.

GSK2263167 is a S1P1 receptor agonist

Sulfadimidine-OVA is a conjugate of Sulfadimidine (HY-B0035) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

NLRP3-IN-68 (Compound 2d) is a 1,3,4-oxadiazole derivative. NLRP3-IN-68 has strong anti-inflammatory and antioxidant activities, which can inhibit inflammatory cytokines secretion, iNOS expression and NLRP3 inflammasome activation. NLRP3-IN-68 can be used in the research of anti-inflammatory drugs.

BVL3572S, a hydroxamic acid derivative, exhibits potent bactericidal activity against Mycobacterium tuberculosis (Mtb) with a MIC₉₀ of 1.7 µM. BVL3572S inhibits pyridoxal phosphate (PLP)-dependent aminotransferases HisC and AlaA to kill Mtb. BVL3572S can be used for tuberculosis (TB) research.

NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the NF-κB signaling pathway. NBD-2 specifically inhibits the typical NF-κB signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to NF-κB signaling pathway, including autoimmune diseases, cancer, etc.

V11294 is a phosphodiesterase 4 (PDE4) inhibitor with a K_i value of 436 nM against human lung PDE4. V11294 exhibits anti-inflammation activity.

1,3,5-Trihydroxy-4-prenylxanthone is a Na⁺/H⁺ exchange system inhibitor with a minimum inhibitory concentration of 10 μg/mL. 1,3,5-Trihydroxy-4-prenylxanthone is a phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 3.0 μM. 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (HY-D1056)-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities.